Sangamo Therapeutics, Inc (SGMOQ): Shareholders' Equity
-$14.27M
As of 2025-12-31
-$18.95M
As of 2026-03-31
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$14.27M | n/m | 2026-03-30, Balance as of period end |
| 2024-12-31 | $22.77M | -72.5% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $82.89M | -71.9% | 2025-03-17, Balance as of period end |
| 2022-12-31 | $294.96M | -21.4% | 2024-03-13, Balance as of period end |
| 2021-12-31 | $375.34M | -24.7% | 2022-02-24, Balance as of period end |
| 2020-12-31 | $498.23M | +15.2% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $432.55M | +18.0% | 2021-02-24, Balance as of period end |
| 2018-12-31 | $366.52M | +95.1% | 2020-02-28, Balance as of period end |
| 2017-12-31 | $187.90M | +38.0% | 2019-03-01, Balance as of period end |
| 2016-12-31 | $136.19M | -29.2% | 2018-03-01, Balance as of period end |
| 2015-12-31 | $192.44M | -6.9% | 2018-03-01, Balance as of period end |
| 2014-12-31 | $206.63M | +69.8% | 2017-02-28, Balance as of period end |
| 2013-12-31 | $121.71M | +87.5% | 2016-02-18, Balance as of period end |
| 2012-12-31 | $64.90M | -19.0% | 2015-02-25, Balance as of period end |
| 2011-12-31 | $80.13M | +43.3% | 2014-02-24, Balance as of period end |
| 2010-12-31 | $55.91M | -22.1% | 2013-02-26, Balance as of period end |
| 2009-12-31 | $71.78M | n/a | 2012-02-23, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | -$14.27M | n/m |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $1.58B | +89.0% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $196.08M | -34.6% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $27.29M | -79.7% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $256.59M | +18.8% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $186.29M | +741.1% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $35.47M | n/m |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $92.25M | +63.6% |
| Scilex Holding Co (SCLX) | 2025-12-31 | -$207.78M | n/m |
Compare SGMOQ, KYMR, VYGR, EDIT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗